Anika Therapeutics Inc (OQ:ANIK)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 32 Wiggins Ave
BEDFORD MA 01730-2315
Tel: 1-781-4579287
Website: https://anika.com
IR: See website
<
Key People
Cheryl Renee Blanchard
President, Chief Executive Officer, Director
Michael L. Levitz
Chief Financial Officer, Executive Vice President, Treasurer
Anne Nunes
Chief Operations Officer, Senior Vice President
David B. Colleran
Executive Vice President, General Counsel, Secretary
   
Business Overview
Anika Therapeutics, Inc. is a joint preservation company focused on developing, manufacturing, and commercializing products based on hyaluronic acid (HA) technology platform. The OA Pain Management product family consists of Monovisc and Orthovisc that provides pain relief from osteoarthritis conditions and Cingal consisting of its cross-linked HA material combined with a fast-acting steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products: Integrity, Tactoset, and Hyalofast; its line of sports medicine solutions repairs and reconstructs damaged ligaments and tendons, and its Arthrosurface portfolio of bone preserving joint technologies, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants. Its Non-Orthopedic product family provides orthopedic applications, including adhesion barrier product, advanced wound care products, and ear, nose and throat products.
Financial Overview
For the fiscal year ended 31 December 2023, Anika Therapeutics Inc revenues increased 7% to $166.7M. Net loss increased from $14.9M to $82.7M. Revenues reflect Orthopedic Joint Preservation and Restoration segment increase of 9% to $54.9M, Joint Pain Management segment increase of 4% to $101.9M, Other segment increase of 33% to $21.8M, United States segment increase of 3% to $123.1M.
Employees: 357 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $299.01M as of Dec 31, 2023
Annual revenue (TTM): $166.66M as of Dec 31, 2023
EBITDA (TTM): -$4.84M as of Dec 31, 2023
Net annual income (TTM): -$82.67M as of Dec 31, 2023
Free cash flow (TTM): -$7.22M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 14,660,000 as of Dec 31, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.